(Q46941491)

English

Response to dual blockade of epidermal growth factor receptor (EGFR) and cycloxygenase-2 in nonsmall cell lung cancer may be dependent on the EGFR mutational status of the tumor

scientific article published in December 2007

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

26 December 2017

http://europepmc.org/abstract/MED/17948911

retracted paper

2 references

Dataset for "Continued use of retracted papers: Temporal trends in citations and (lack of) awareness of retractions shown in citation contexts in biomedicine"

Continued use of retracted papers: Temporal trends in citations and (lack of) awareness of retractions shown in citation contexts in biomedicine

Response to dual blockade of epidermal growth factor receptor (EGFR) and cycloxygenase-2 in nonsmall cell lung cancer may be dependent on the EGFR mutational status of the tumor (English)

1 reference

Europe PubMed Central

26 December 2017

http://europepmc.org/abstract/MED/17948911

Fazlul H. Sarkar

6

object named as

Fazlul H Sarkar

1 reference

Europe PubMed Central

26 December 2017

http://europepmc.org/abstract/MED/17948911

author name string

Shirish M Gadgeel

1

1 reference

Europe PubMed Central

26 December 2017

http://europepmc.org/abstract/MED/17948911

Shadan Ali

2

1 reference

Europe PubMed Central

26 December 2017

http://europepmc.org/abstract/MED/17948911

Philip A Philip

3

1 reference

Europe PubMed Central

26 December 2017

http://europepmc.org/abstract/MED/17948911

Fakhara Ahmed

4

1 reference

Europe PubMed Central

26 December 2017

http://europepmc.org/abstract/MED/17948911

Antoinette Wozniak

5

1 reference

Europe PubMed Central

26 December 2017

http://europepmc.org/abstract/MED/17948911

language of work or name

0 references

publication date

1 December 2007

1 reference

Europe PubMed Central

26 December 2017

http://europepmc.org/abstract/MED/17948911

1 reference

Europe PubMed Central

26 December 2017

http://europepmc.org/abstract/MED/17948911

110

1 reference

Europe PubMed Central

26 December 2017

http://europepmc.org/abstract/MED/17948911

12

1 reference

Europe PubMed Central

26 December 2017

http://europepmc.org/abstract/MED/17948911

2775-2784

1 reference

Europe PubMed Central

26 December 2017

http://europepmc.org/abstract/MED/17948911

ErbB-targeted therapeutic approaches in human cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23100

21 January 2018

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23100

21 January 2018

Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23100

21 January 2018

Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23100

21 January 2018

Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23100

21 January 2018

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23100

21 January 2018

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23100

21 January 2018

Mutations and addiction to EGFR: the Achilles 'heal' of lung cancers?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23100

21 January 2018

Combined targeting of the epidermal growth factor receptor and cyclooxygenase-2 pathways

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23100

21 January 2018

Cyclooxygenases: structural, cellular, and molecular biology

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23100

21 January 2018

Regulation of the immune response by prostaglandins

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23100

21 January 2018

Prostaglandin E2 increases growth and motility of colorectal carcinoma cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23100

21 January 2018

Cyclooxygenase regulates angiogenesis induced by colon cancer cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23100

21 January 2018

Prostaglandin E2 regulates cell migration via the intracellular activation of the epidermal growth factor receptor

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23100

21 January 2018

Targeting cyclooxygenase-2 in human neoplasia: rationale and promise

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23100

21 January 2018

Prostaglandin E2 transactivates EGF receptor: a novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23100

21 January 2018

Cyclooxygenase-2-dependent regulation of E-cadherin: prostaglandin E(2) induces transcriptional repressors ZEB1 and snail in non-small cell lung cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23100

21 January 2018

Erlotinib in previously treated non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23100

21 January 2018

Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23100

21 January 2018

A phase I trial to determine the optimal biological dose of celecoxib when combined with erlotinib in advanced non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23100

21 January 2018

Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non-small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23100

21 January 2018

Annual report to the nation on the status of cancer, 1975-2002, featuring population-based trends in cancer treatment

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23100

7 January 2021

based on heuristic

inferred from DOI database lookup

Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23100

7 January 2021

based on heuristic

inferred from DOI database lookup

Prostaglandin endoperoxide synthase: regulation of enzyme expression

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23100

7 January 2021

based on heuristic

inferred from DOI database lookup

Cyclooxygenase-2 inhibitors in tumorigenesis (Part II)

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23100

7 January 2021

based on heuristic

inferred from DOI database lookup

Combinatorial chemoprevention of intestinal neoplasia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23100

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II study of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), and celecoxib, a cyclooxygenase-2 (COX-2) inhibitor, in patients with platinum refractory non-small cell lung cancer (NSCLC).

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23100

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CNCR.23100

1 reference

Europe PubMed Central

26 December 2017

http://europepmc.org/abstract/MED/17948911

1 reference

Europe PubMed Central

26 December 2017

http://europepmc.org/abstract/MED/17948911

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46941491&oldid=2139004978"